Laurus Labs Limited Earnings Summary — Q1 FY2027
Laurus Labs Delivers Sharp Recovery with Q1 Profit Scaling 124% YoY
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 5 consecutive quarters.
- Revenue of ₹2,026 Cr is 29.1% higher year-on-year.
- Revenue has compounded at 16.4% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹368 Cr is 125.5% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 101.9% annualised across the period.
- Operating margin stands at 31.5% in Q1 FY2027.
- Operating margin expanded by 715 bps year-on-year.
- Over the last two years operating margin has expanded by 1717 bps.
- PBT margin is 23.8%.
- Expense growth of 16.9% remained below revenue growth of 29.1%.
- Operating profit of ₹638 Cr is 67.0% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 89/100 (Excellent) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 2,026 | 1,812 | 1,778 | 1,653 | 1,570 | 1,720 | 1,415 | 1,224 | 1,195 | 1,440 |
| Expenses | Stable | 1,388 | 1,299 | 1,298 | 1,250 | 1,187 | 1,300 | 1,130 | 1,045 | 1,024 | 1,198 |
| Operating Profit | Strong Uptrend | 638 | 512 | 480 | 403 | 382 | 421 | 285 | 178 | 171 | 241 |
| Operating Margin | Improving | 31.5% | 28.3% | 27.0% | 24.4% | 24.4% | 24.4% | 20.1% | 14.6% | 14.3% | 16.8% |
| Other Income | Volatile | 9 | 12 | 6 | 27 | 10 | 59 | 9 | 5 | 3 | 19 |
| Interest | Stable | 42 | 40 | 39 | 40 | 52 | 56 | 58 | 53 | 49 | 51 |
| Depreciation | Stable | 124 | 122 | 121 | 120 | 117 | 110 | 106 | 108 | 106 | 102 |
| Profit Before Tax | Volatile | 481 | 361 | 327 | 270 | 224 | 312 | 131 | 23 | 18 | 107 |
| Tax | Volatile | 119 | 79 | 73 | 76 | 63 | 78 | 40 | 5 | 6 | 32 |
| Net Profit | Strong Uptrend | 368 | 279 | 252 | 195 | 163 | 234 | 92 | 20 | 13 | 76 |
| Net Margin | Volatile | 18.1% | 15.4% | 14.2% | 11.8% | 10.4% | 13.6% | 6.5% | 1.6% | 1.1% | 5.3% |
Key Takeaways
- Revenue witnessed strong momentum, growing 29% YoY to reach ₹2,026 cr, driven by recovery across segments.
- Net profit saw a massive jump of 124% YoY, reflecting significant margin expansion as operating leverage improved.
- The quarter showed strong sequential improvement (QoQ), with Profit After Tax rising 28% compared to Q4 FY26.
- Finance costs decreased significantly on a YoY basis to ₹42.22 cr (vs ₹51.50 cr), aiding bottom-line growth.
- The company is proceeding with a Composite Scheme of Arrangement for demerging and merging various synthesis units to optimize operations.
- Depreciation and amortisation expenses remained stable at ₹123.87 cr, indicating high asset utilization.
- Total comprehensive income attributable to equity holders stood at ₹365.39 cr, highlighting robust underlying performance.
Management Guidance
Management is focused on capitalising on 'China+1' sourcing shifts and transitioning from ARV API focus to a high-margin integrated CDMO platform.
Sentiment Shift
Improving
The results mark a clear departure from the margin compression seen in previous years, with high growth returning to both top and bottom lines.
Outlook
The company remains on a trajectory of structural recalibration, leveraging its massive R&D workforce and newly commissioned capacities to target higher-margin CDMO global sourcing opportunities.
From the Annual Report (Key Quotes)
“Chemistry for Better Living”
“The statutory auditors have issued an unmodified conclusion in respect of the limited review.”
“Implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Laurus Labs Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.